Fiasp® (fast-acting insulin aspart) approved in Europe


10.01.17 14:20
Meldung
 
Fiasp® (fast-acting insulin aspart) approved in Europe Bagsværd, Denmark, 10 January 2017 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Fiasp® for the treatment of diabetes in adults. The authorisation covers all 28 European Union member states.

Fiasp® is the brand name for fast-acting insulin aspart. Fiasp® provides improved mealtime and overall glucose control with a similar safety profile versus NovoRapid®.

"Fiasp® is a new-generation mealtime insulin; it is an innovative faster formulation of insulin aspart that more closely mimics the physiological insulin response around meals. The incremental benefits with Fiasp® are comparable to those observed for the last generation of mealtime insulins when introduced more than a decade ago", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Fiasp® will be available in vial, Penfill® and FlexTouch® pen.

Novo Nordisk expects to launch Fiasp® in the first European countries in the first half of 2017.

About Fiasp®

Fiasp® (fast-acting insulin aspart) is an ultra-fast rapid-acting insulin now approved in Europe that improves control of postprandial glucose (PPG) excursions and has been developed for the treatment of people with type 1 and type 2 diabetes, as well as for pump treatment.

Fiasp® is insulin aspart (NovoRapid®) in a new formulation, in which two new excipients have been added to ensure earlier, greater and faster absorption, thereby providing earlier insulin action. The review of Fiasp® was based on the onset programme, a phase 3 clinical programme comprising of four trials encompassing more than 2,100 people with type 1 and type 2 diabetes.

Fiasp® also received marketing authorisation from Health Canada on 6 January 2017, and has been filed for regulatory review in the US, Switzerland, Australia, Canada, Brazil, South Africa and Argentina.

Further information

Media:    
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 3 / 2017








This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

Novo-Nordisk

Aktuelle Diskussionen zum Thema:

Novo-Nordisk - Insulinpräparate (23.01.17)
Dividenden-Giganten (10.12.16)
Thema Diabetis-Insulien (23.02.15)

Aktuelle Nachrichten zum Unternehmen:

Novo Nordisk-Aktie: Q4-Zahlen dür. (23.01.17)
Novo Nordisk-Aktie: Positive Währ. (23.01.17)
Novo Nordisk erhält EU-Zulassung . (10.01.17)
Novo Nordisk-Aktie: Ende der Talf. (29.12.16)
Novo Nordisk-Aktie: Solche Gelege. (02.12.16)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Novo-Nordisk
Weitere Meldungen
 
10.01 Fiasp® (fast-acting insulin a.
10.01 Ahlstrom announces positive.
10.01 Ad hoc: HumanOptics AG e.
10.01 Talvivaara Mining Company .
10.01 The court of arbitration dism.
10.01 L'ORÉAL: News Release: "L.
10.01 EQS-Adhoc: ACRON HELVE.
09.01 EVS Broadcast Equipment: .
09.01 Agfa-Gevaert : Classic Fund.
09.01 EQS-Adhoc: LifeWatch AG:.
09.01 Ad hoc: MAX 21 AG führt.
09.01 Ad hoc: Accentro Real Esta.
09.01 Ad hoc: PANTALEON Ente.
09.01 Ad hoc: Bijou Brigitte modis.
09.01 Ad hoc: PNE WIND AG ve.
09.01 Ad hoc: Neschen AG: Verä.
09.01 Outotec and Outokumpu sett.
09.01 ANDREW ROBINSON NAM.
09.01 The European Patent Office.
09.01 Ahold Delhaize commences .
09.01 Cancellation of Extraordinary.
09.01 TGS Q4 2016 Update and .
09.01 SOITEC : Launch of the rev.
09.01 DBV Technologies Announce.
09.01 Addex ADX71441 Demonstr.
09.01 Takeda notifies 4.48% share.
09.01 DNO Makes Cretaceous Oil .
08.01 Ad hoc: Die Geschäftsführu.
07.01 Ad hoc: Fresenius Medical C.
06.01 Ad hoc: Pütz Vermögensver.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 19704 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Nordex SE: Ist das Schlimmste vorbei?
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
DOW DAX ...
Thomas Heydrich, Systemstradings.de (23.01.17)
Experte: Thomas Heydrich, Systemstradings.de
Devin Sage TXA Trading ...
Devin Sage, Technische-X-Analyse.de (23.01.17)
Experte: Devin Sage, Technische-X-Analyse.de
DAX verliert nach Trump-...
CMC Markets, (23.01.17)
Experte: CMC Markets,
Volkswagen geadelt
Feingold-Research, (23.01.17)
Experte: Feingold-Research,
Aus voller Überzeugung in ...
Stephan Bogner, Rockstone Research (23.01.17)
Experte: Stephan Bogner, Rockstone Research
Ohne Kobalt keine Zukunft
Ingrid Heinritzi, (23.01.17)
Experte: Ingrid Heinritzi,
"America First" - US-...
Cornelia Frey, Börse Stuttgart AG (23.01.17)
Experte: Cornelia Frey, Börse Stuttgart AG
S&P-500-Index: Ausblick
Christian Zoller, www.boerse-daily.de (23.01.17)
Experte: Christian Zoller, www.boerse-daily.de
Ein dynamischer Ausbruch ...
Silvio Graß, Formationstrader (23.01.17)
Experte: Silvio Graß, Formationstrader
Ist Trump eingepreist? - ...
Jewgeni Ponomarev, Zertifikate-Experte HSB. (23.01.17)
Experte: Jewgeni Ponomarev, Zertifikate-Experte HSBC Trinkaus
DAX: Nun wird es ...
Robert Sasse, (23.01.17)
Experte: Robert Sasse,
Gold/USD: Der Glanz kehrt ...
DONNER & REUSCHEL., (23.01.17)
Experte: DONNER & REUSCHEL AG,
Niquet's World
Neues vom Portal
 
Differenzkontrakte als Geldanlage
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen